Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger

S. H. Harouna, N. Ortuno-Gutierrez, M. B. Souleymane, W. Kizito, S. Morou, AR Boukary, Maria Zolfo, G. Benedetti, A. Piubello

Research output: Contribution to journalA1: Web of Science-articlepeer-review

2 Downloads (Pure)


Setting: Niger National Tuberculosis Programme.

Objective: To describe the outcomes and adverse events (AEs) in a cohort of adults, children and adolescents with multidrug-resistant tuberculosis (MDR-TB) who were treated with the 'short-course regimen'.

Design: The regimen comprised an intensive phase of 4-6 months with kanamycin, medium-high dose of isoniazid and prothionamide, and high doses of gatifloxacin, clofazimine, ethambutol and pyrazinamide throughout. Sixty-five patients were treated with a regimen of 12-14 months and 55 patients with a regimen of 9-11 months.

Results: Of the 120 patients evaluated, 110 (92%) were adults (median age 31 years) and 10 (8%) were children or adolescents (median age 17 years). The treatment success rate was respectively 88% and 83% with the 9-month regimen, and 90% and 75% with the 12-month regimen in adults and children/adolescents. Initial resistance to ethambutol and prothionamide did not affect treatment success rates but resistance to fluoroquinolones did, although this was not statistically significant. Vomiting was the most frequently encountered AE, followed by ototoxicity and hepatotoxicity. AEs experienced were mild or moderate in severity in most patients, and did not lead to treatment interruption.

Conclusion: These results confirm the programmatic effectiveness and tolerability of the shorter regimen in second-line drug-naive patients.

Original languageEnglish
JournalInternational Journal of Tuberculosis and Lung Disease
Issue number5
Pages (from-to)625-630
Number of pages6
Publication statusPublished - 2019


  • MDR-TB
  • children/adolescent
  • short-course
  • Niger


Dive into the research topics of 'Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger'. Together they form a unique fingerprint.

Cite this